Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences

Imaging biomarkers correlate with efficacy of bevacizumab combined with conventional therapy in newly diagnosed glioblastoma: an open-label, single arm trial

Li Li, Shuanghu Yuan, Jinming Yu, Ning Liu, Zhang Hui, Rongjie Tao, Shuqiang Zhao, Liang Xu, Yuhui Liu and Yongsheng Gao
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 492;
Li Li
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuanghu Yuan
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinming Yu
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ning Liu
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhang Hui
1Linyi Cancer Hospital Linyi China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rongjie Tao
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuqiang Zhao
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhui Liu
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongsheng Gao
2Shandong Cancer Hospital and Institute Jinan China
3Shandong Cancer Hospital and Institute Jinan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

492

Purpose: To investigate the ability of potential imaging biomarkers to predict the response of bevacizumab (known as Avastin) combined with conventional therapy in newly diagnosed glioblastoma. Materials and Methods: Patients newly diagnosed with glioblastoma after surgery were enrolled to receive Avastin plus conventional concurrent radiotherapy and temozolomide. 18F-AlF-NOTA-PRGD2 positron emission tomography/computed tomography (18F-RGD PET/CT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) were performed at baseline, week 3, and week 10 for each patient. Molecular information was assessed in patients’ tumor tissue. Statistical methods included the Kaplan-Meier method as well as univariate and multivariate Cox proportional hazard models. This trial was registered with Clinicaltrials.gov, number NCT01939574, ID ML28676.

Results: Twenty patients were prospectively enrolled, and the median follow-up time was 16 months (range, 4-42 months). The median progression-free survival (PFS) was 9.66 months (95% confidence interval [CI], 6.20-13.12 months). Parameters on 18F-RGD PET/CT and DCE MRI at baseline and changes from baseline to week 10 were found not to be predictive of PFS. However, a greater decrease in the mean standard uptake value (SUVmean) from week 3 to week 10 was associated with better PFS (12.3 vs. 7.5 months, log rank p=0.009). In addition, low expression levels of epidermal growth factor receptor and vascular endothelial growth factor (VEGFA) were significantly associated with a longer PFS (7.46 vs. 11.40 months, p=0.045; high vs. low, 8.02 vs. 11.40 months, p=0.028). Isocitrate dehydrogenase 1 appeared to prolong PFS, but the association was not statistically significant (mutation vs. non-mutation, 4.2 vs. 10.8 months, p=0.065). Multivariate Cox hazard models were derived for PFS initially using clinical factors such as age, gender, smoking history, Karnofsky performance status, and parameters for which p<0.1. A greater decrease in SUVmean before and after Avastin treatment remained a signficant predictor of better PFS independent of VEGFA expression (95% CI, 1.82-11575.72, p=0.026).

Conclusions: 18F-RGD PET/CT may be valuable in assessing the response of glioblastoma to treatment with the combination of Avastin and CCRT, with a greater decrease in SUVmean predicting better PFS.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Imaging biomarkers correlate with efficacy of bevacizumab combined with conventional therapy in newly diagnosed glioblastoma: an open-label, single arm trial
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Imaging biomarkers correlate with efficacy of bevacizumab combined with conventional therapy in newly diagnosed glioblastoma: an open-label, single arm trial
Li Li, Shuanghu Yuan, Jinming Yu, Ning Liu, Zhang Hui, Rongjie Tao, Shuqiang Zhao, Liang Xu, Yuhui Liu, Yongsheng Gao
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 492;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Imaging biomarkers correlate with efficacy of bevacizumab combined with conventional therapy in newly diagnosed glioblastoma: an open-label, single arm trial
Li Li, Shuanghu Yuan, Jinming Yu, Ning Liu, Zhang Hui, Rongjie Tao, Shuqiang Zhao, Liang Xu, Yuhui Liu, Yongsheng Gao
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 492;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences

  • PET CT Quantification to direct Alzheimer’s patients to anti-amyloid therapy
  • Multicenter trial study for usefulness of physical parameters toward the standardization of brain SPECT image: relation to visual analysis
  • Assessment of Brain Perfusion 123I-IMP SPECT imaging Using Low Energy High Resolution Collimator image reconstructed by Flash 3D
Show more Neurosciences

Brain Imaging Reloaded II

  • Altered Brain Metabolism and Connectivity in Somatoform Disorders: an 18F-FDG PET Study
  • Effect of Deep brain stimulation on the brain metabolic pattern in patients with Depression: Comparison of pre and post therapy PET/CT scans-A pilot study.
  • Implementation of 6-[18F]FDOPA PET/CT for management of brain tumors growth and post-irradiation changes: Preliminary results from Azerbaijan
Show more Brain Imaging Reloaded II

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire